Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LB2102 · 1 trial · 2 indications
Multiple doses will be tested to establish a recommended dose
Treatment of additional patients at the recommended dose as identified in the initial dose escalation part of the study
| Arm | Type | Description |
|---|---|---|
| Experimental LB2102 | EXPERIMENTAL | DLL3-Directed Chimeric Antigen Receptor T-cells (CAR T) |
| Name | Type | Description |
|---|---|---|
| LB2102 | BIOLOGICAL | DLL3 directed autologous Chimeric Antigen Receptor T-cells |
Inclusion Criteria: * Be at least 18 years of age and willing and able to provide a written informed consent * Have histologically/cytologically confirmed unresectable small cell lung carcinoma (SCLC), large cell neuroendocrine lung carcinoma (LCNEC), combined SCLC, or combined LCNEC as per WHO 202...
LB2102 is an investigational therapy being developed for extensive stage small cell lung cancer. It is also being studied in large cell neuroendocrine carcinoma of the lung. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LB2102 targets DLL3, a protein expressed on the surface of certain cancer cells. By directing chimeric antigen receptor T-cells against DLL3, the therapy aims to recognize and attack DLL3-positive tumor cells in extensive stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung.
LB2102 is being developed by Legend Biotech Corporation, a biopharmaceutical company listed on the stock exchange under the ticker LEGN. The company is conducting clinical trials to evaluate the safety and efficacy of LB2102 in patients with extensive stage small cell lung cancer.
LB2102 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is active but not recruiting participants, and the drug is being studied in the United States.
LB2102 is being evaluated in a Phase 1 clinical trial with the identifier NCT05680922. The trial is titled 'DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer' and is enrolling approximately 41 participants aged 18 years and older in the United States.
Yes, LB2102 is a DLL3-directed chimeric antigen receptor (CAR) T-cell therapy. It is designed to target the DLL3 protein, which is found on cancer cells in extensive stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung. The therapy is currently in Phase 1 clinical trials.